Asymchem Inaugurates Its First European Small Molecule Development and API Pilot Plant Manufacturing Site at Discovery Park in Sandwich, Kent, UK
02 Agosto 2024 - 12:58PM
Business Wire
Asymchem Laboratories (Tianjin) Co., Ltd. (Stock Code
002821.SZ/6821.HK) announced today that it has officially
inaugurated its new European development and pilot manufacturing
site at Discovery Park in Sandwich, Kent, U.K., marked with a
ribbon cutting by Dr. Hao Hong, Chairman, Founder, and CEO of
Asymchem.
The former Pfizer small molecule facilities now employ 70 team
members on-site in both the R&D labs and the API pilot plant,
many of whom are legacy Pfizer employees. Additional hires are
planned through to the end of the year as the pilot plant ramps up
operations.
Building on a foundation of utilizing innovative technologies to
enable smarter, greener, and cost-effective solutions to support
manufacture, Asymchem will add additional capabilities on-site.
Advanced equipment for the manufacture of peptides and
oligonucleotides, as well as sustainability capabilities for
continuous flow and biocatalysis, will be added by 2025.
Hong said: “This is an exciting milestone for Asymchem to meet
growing demand for pharma services and supply. We are continuing a
long legacy of manufacturing excellence at Discovery Park, with the
location in Kent being ideal for reaching our target markets in
Europe.”
Mayer Schreiber, CEO of Discovery Park, said: “We are thrilled
to see Asymchem join our thriving community at Discovery Park. We
believe Kent is the ideal location for a European HQ, providing
fast connections to both Europe and the capital, along with all
important space to grow. Many of the team members at Asymchem have
been working at Discovery Park for decades, and we’re delighted to
continue to support and champion the talent here.”
About Asymchem
Asymchem is a global technology-driven contract development and
manufacturing organization (CDMO) providing services to the
pharmaceutical industry. Founded in 1997, Asymchem employs over
9700 personnel world-wide, with R&D and manufacturing
operations in the UK, U.S. and China.
Our one-stop solutions range from early clinical to
commercialization, including R&D and cGMP production of small
molecule to chemical macromolecule of advanced intermediates, APIs,
formulation, as well as clinical research services. Leveraging our
deep industry insights accumulated over 25 years, Asymchem plays an
integral part of the global pharmaceutical supply chain for
innovative drugs.
Forward-Looking Statements
This press release may contain certain forward-looking
statements that are, by their nature, subject to significant risks
and uncertainties. The words “anticipate,” “believe,” “estimate,”
“expect,” “intend” and similar expressions, as they relate to the
Company, are intended to identify certain of such forward-looking
statements. The Company does not intend to update these
forward-looking statements regularly. These forward-looking
statements are based on the existing beliefs, assumptions,
expectations, estimates, projections, and understandings of the
management of the Company with respect to future events at the time
these statements are made. These statements are not a guarantee of
future developments and are subject to risks, uncertainties, and
other factors, some of which are beyond the Company’s control and
are difficult to predict. Consequently, actual results may differ
materially from information contained in the forward-looking
statements as a result of a number of factors, including, without
limitation, future changes or developments in our business, the
Company’s competitive environment and political, economic, legal
and social conditions.
The Company, its directors and the employees assume (a) no
obligation to correct or update the forward-looking statements
contained in this announcement; and (b) no liability in the event
that any of the forward-looking statements does not materialize or
turn out to be incorrect.
About Discovery Park
Discovery Park is a thriving life science community for
visionary entrepreneurs and leaders and the ideal environment for
businesses to start, scale and succeed. It offers state-of-the-art
labs, modern offices and manufacturing facilities, unrivalled
flexibility and comprehensive support including access to finance
and a strong local talent pool. Discovery Park has been a major
centre for life science for nearly 70 years and is home to 160+
companies across a growing tenant community of dynamic start-ups
through to global corporations. This includes Pfizer, Asymchem,
Viatris, Concept Life Sciences, Canterbury Christ Church
University, York Bio, Resolian, Psyros Diagnostics, VisusNano,
Cummins and eXroid. Within easy reach of London, Discovery Park
spearheads Kent’s flourishing science and technology cluster. As an
extension of the Golden Triangle, Discovery Park’s location
provides access to a wealth of resources and opportunities, coupled
with an enviable quality of life.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240802011861/en/
Asymchem Inc. Jake Knorr Senior Director of Marketing
jakeknorr@asymchem.com
Discovery Park Kirsty Budden Head of Marketing, Discovery
Park kirsty.budden@discovery-park.co.uk +44 (0) 7730 618514
Perceptive Communicators, Media Relations
Sophie Newington sophie.newington@perceptivecommunicators.co.uk
+44 (0)7735 580418 Notes for Editors